Emerging role of the KRAS-PDK1 axis in pancreatic cancer

World Journal of Gastroenterology

Volumn 20, Issue 31, 2014, Pages 10752-10757

  Ferro, Riccardo ^a   Falasca, Marco ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

3 phosphoinositide dependent protein kinase 1; KRAS; Pancreatic cancer; Phosphoinositide 3 kinase; Signal transduction

Indexed keywords

K RAS PROTEIN; MICRORNA 375; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE; KRAS PROTEIN, HUMAN; MICRORNA; MIRN375 MICRORNA, HUMAN; ONCOPROTEIN; PDPK1 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; RAS PROTEIN;

CANCER PROGNOSIS; CANCER THERAPY; GENE MUTATION; HUMAN; NONHUMAN; ONCOGENE RAS; PANCREAS CANCER; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW; SURVIVAL RATE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DESIGN; DRUG EFFECTS; ENZYMOLOGY; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION; PANCREATIC NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION;

3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASES; ANIMALS; DRUG DESIGN; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; MUTATION; PANCREATIC NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84909582372     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i31.10752     Document Type: Review

References (49)

1. Yachida S, Iacobuzio-Donahue CA. Evolution and dynamics of pancreatic cancer progression. Oncogene 2013; 32: 5253-5260 [PMID: 23416985 DOI: 10.1038/onc.2013.29]
2. Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA, Michor F. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell 2012; 148: 362-375 [PMID: 22265421 DOI: 10.1016/j.cell.2011.11.060]
3. Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin Cancer Res 2000; 6: 2969-2972 [PMID: 10955772]
4. Hruban RH, Wilentz RE, Kern SE. Genetic progression in the pancreatic ducts. Am J Pathol 2000; 156: 1821-1825 [PMID: 10854204 DOI: 10.1016/S0002-9440(10)65054-7]
5. Morris JP, Wang SC, Hebrok M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer 2010; 10: 683-695 [PMID: 20814421 DOI: 10.1038/nrc2899]
6. Hruban RH, Adsay NV, Albores-Saavedra J, Compton C, Garrett ES, Goodman SN, Kern SE, Klimstra DS, Klöppel G, Longnecker DS, Lüttges J, Offerhaus GJ. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 2001; 25: 579-586 [PMID: 11342768]
7. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio- Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321: 1801-1806 [PMID: 18772397 DOI: 10.1126/science.1164368]
8. Hruban RH, van Mansfeld AD, Offerhaus GJ, van Weering DH, Allison DC, Goodman SN, Kensler TW, Bose KK, Cameron JL, Bos JL. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993; 143: 545-554 [PMID: 8342602]
9. Shibata D, Almoguera C, Forrester K, Dunitz J, Martin SE, Cosgrove MM, Perucho M, Arnheim N. Detection of c-K-ras mutations in fine needle aspirates from human pancreatic adenocarcinomas. Cancer Res 1990; 50: 1279-1283 [PMID: 2404591]
10. Agbunag C, Bar-Sagi D. Oncogenic K-ras drives cell cycle progression and phenotypic conversion of primary pancreatic duct epithelial cells. Cancer Res 2004; 64: 5659-5663 [PMID: 15313904 DOI: 10.1158/0008-5472.CAN-04-0807]
11. Campbell PM, Groehler AL, Lee KM, Ouellette MM, Khazak V, Der CJ. K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res 2007; 67: 2098-2106 [PMID: 17332339 DOI: 10.1158/0008-5472. CAN-06-3752]
12. 12D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin. Br J Cancer 2011; 104: 1038-1048 [PMID: 21364589 DOI: 10.1038/bjc.2011.31]
13. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011; 11: 761-774 [PMID: 21993244 DOI: 10.1038/nrc3106]
14. di Magliano MP, Logsdon CD. Roles for KRAS in pancreatic tumor development and progression. Gastroenterology 2013; 144: 1220-1229 [PMID: 23622131 DOI: 10.1053/j.gastro.2013.01.071]
15. Hofmann I, Weiss A, Elain G, Schwaederle M, Sterker D, Romanet V, Schmelzle T, Lai A, Brachmann SM, Bentires-Alj M, Roberts TM, Sellers WR, Hofmann F, Maira SM. K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo. PLoS One 2012; 7: e44146 [PMID: 22952903 DOI: 10.1371/journal.pone.0044146]
16. Arvanitakis M, Van Laethem JL, Parma J, De Maertelaer V, Delhaye M, Devière J. Predictive factors for pancreatic cancer in patients with chronic pancreatitis in association with K-ras gene mutation. Endoscopy 2004; 36: 535-542 [PMID: 15202051 DOI: 10.1055/s-2004-814401]
17. Falasca M, Selvaggi F, Buus R, Sulpizio S, Edling CE. Targeting phosphoinositide 3-kinase pathways in pancreatic cancer - from molecular signalling to clinical trials. Anticancer Agents Med Chem 2011; 11: 455-463 [PMID: 21521159 DOI: 10.2174/187152011795677382]
18. Siveke JT, Crawford HC. KRAS above and beyond - EGFR in pancreatic cancer. Oncotarget 2012; 3: 1262-1263 [PMID: 23174662]
19. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008; 27: 5497-5510 [PMID: 18794884 DOI: 10.1038/onc.2008.245]
20. Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 2004; 3: 1221-1224 [PMID: 15467468 DOI: 10.4161/cc.3.10.1164]
21. Zhao L, Vogt PK. Class I PI3K in oncogenic cellular transformation. Oncogene 2008; 27: 5486-5496 [PMID: 18794883 DOI: 10.1038/onc.2008.244]
22. Edling CE, Selvaggi F, Buus R, Maffucci T, Di Sebastiano P, Friess H, Innocenti P, Kocher HM, Falasca M. Key role of phosphoinositide 3-kinase class IB in pancreatic cancer. Clin Cancer Res 2010; 16: 4928-4937 [PMID: 20876794 DOI: 10.1158/1078-0432.CCR-10-1210]
23. Raimondi C, Falasca M. Targeting PDK1 in cancer. Curr Med Chem 2011; 18: 2763-2769 [PMID: 21568903]
24. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 1999; 96: 4240-4245 [PMID: 10200246 DOI: 10.1073/pnas.96.8.4240]
25. Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL, Reddy SA. The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NFkappaB and c-Myc in pancreatic cancer cells. Oncogene 2004; 23: 8571-8580 [PMID: 15467756 DOI: 10.1038/sj.onc.1207902]
26. Hill R, Calvopina JH, Kim C, Wang Y, Dawson DW, Donahue TR, Dry S, Wu H. PTEN loss accelerates KrasG12D-induced pancreatic cancer development. Cancer Res 2010; 70: 7114-7124 [PMID: 20807812 DOI: 10.1158/0008-5472.CAN-10-1649]
27. Schlieman MG, Fahy BN, Ramsamooj R, Beckett L, Bold RJ. Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer 2003; 89: 2110-2115 [PMID: 14647146 DOI: 10.1038/sj.bjc.6601396]
28. Yamamoto S, Tomita Y, Hoshida Y, Morooka T, Nagano H, Dono K, Umeshita K, Sakon M, Ishikawa O, Ohigashi H, Nakamori S, Monden M, Aozasa K. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res 2004; 10: 2846-2850 [PMID: 15102693 DOI: 10.1158/1078-0432.CCR-02-1441]
29. Elghazi L, Weiss AJ, Barker DJ, Callaghan J, Staloch L, Sandgren EP, Gannon M, Adsay VN, Bernal-Mizrachi E. Regulation of pancreas plasticity and malignant transformation by Akt signaling. Gastroenterology 2009; 136: 1091-1103 [PMID: 19121634 DOI: 10.1053/j.gastro.2008.11.043]
30. Schmid MC, Avraamides CJ, Dippold HC, Franco I, Foubert P, Ellies LG, Acevedo LM, Manglicmot JR, Song X, Wrasidlo W, Blair SL, Ginsberg MH, Cheresh DA, Hirsch E, Field SJ, Varner JA. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression. Cancer Cell 2011; 19: 715-727 [PMID: 21665146 DOI: 10.1016/j.ccr.2011.04.016]
31. Gagliardi PA, di Blasio L, Orso F, Seano G, Sessa R, Taverna D, Bussolino F, Primo L. 3-phosphoinositide-dependent kinase 1 controls breast tumor growth in a kinase-dependent but Akt-independent manner. Neoplasia 2012; 14: 719-731 [PMID: 22952425]
32. Eser S, Reiff N, Messer M, Seidler B, Gottschalk K, Dobler M, Hieber M, Arbeiter A, Klein S, Kong B, Michalski CW, Schlitter AM, Esposito I, Kind AJ, Rad L, Schnieke AE, Baccarini M, Alessi DR, Rad R, Schmid RM, Schneider G, Saur D. Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. Cancer Cell 2013; 23: 406-420 [PMID: 23453624 DOI: 10.1016/j.ccr.2013.01.023]
33. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A, Simendinger J, Li T, Padera RF, García-Echeverría C, Weissleder R, Mahmood U, Cantley LC, Wong KK. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008; 14: 1351-1356 [PMID: 19029981 DOI: 10.1038/nm.1890]
34. Falasca M, Chiozzotto D, Godage HY, Mazzoletti M, Riley AM, Previdi S, Potter BV, Broggini M, Maffucci T. A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate. Br J Cancer 2010; 102: 104-114 [PMID: 20051961 DOI: 10.1038/sj.bjc.6605408]
35. Tan J, Li Z, Lee PL, Guan P, Aau MY, Lee ST, Feng M, Lim CZ, Lee EY, Wee ZN, Lim YC, Karuturi RK, Yu Q. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy. Cancer Discov 2013; 3: 1156-1171 [PMID: 23887393 DOI: 10.1158/2159-8290.CD-12-0595]
36. Ischenko I, Zhi J, Moll UM, Nemajerova A, Petrenko O. Direct reprogramming by oncogenic Ras and Myc. Proc Natl Acad Sci USA 2013; 110: 3937-3942 [PMID: 23431158]
37. Wang GM, Wong HY, Konishi H, Blair BG, Abukhdeir AM, Gustin JP, Rosen DM, Denmeade SR, Rasheed Z, Matsui W, Garay JP, Mohseni M, Higgins MJ, Cidado J, Jelovac D, Croessmann S, Cochran RL, Karnan S, Konishi Y, Ota A, Hosokawa Y, Argani P, Lauring J, Park BH. Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation. Cancer Res 2013; 73: 3248-3261 [PMID: 23580570 DOI: 10.1158/0008-5472.CAN-12-1578]
38. Garcia-Carracedo D, Turk AT, Fine SA, Akhavan N, Tweel BC, Parsons R, Chabot JA, Allendorf JD, Genkinger JM, Remotti HE, Su GH. Loss of PTEN expression is associated with poor prognosis in patients with intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res 2013; 19: 6830-6841 [PMID: 24132918 DOI: 10.1158/1078-0432.CCR-13-0624]
39. Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol 2014; 9: 287-314 [PMID: 24079833 DOI: 10.1146/annurev.pathol.4.110807.092222]
40. Khan S, Ansarullah D, Jaggi M, Chauhan SC. Targeting microRNAs in pancreatic cancer: microplayers in the big game. Cancer Res 2013; 73: 6541-6547 [PMID: 24204026 DOI: 10.1158/0008-5472.CAN-13-1288]
41. LaConti JJ, Shivapurkar N, Preet A, Deslattes Mays A, Peran I, Kim SE, Marshall JL, Riegel AT, Wellstein A. Tissue and serum microRNAs in the Kras(G12D) transgenic animal model and in patients with pancreatic cancer. PLoS One 2011; 6: e20687 [PMID: 21738581 DOI: 10.1371/journal.pone.0020687]
42. Yabushita S, Fukamachi K, Tanaka H, Sumida K, Deguchi Y, Sukata T, Kawamura S, Uwagawa S, Suzui M, Tsuda H. Circulating microRNAs in serum of human K-ras oncogene transgenic rats with pancreatic ductal adenocarcinomas. Pancreas 2012; 41: 1013-1018 [PMID: 22513294 DOI: 10.1097/MPA.0b013e31824ac3a5]
43. Yan JW, Lin JS, He XX. The emerging role of miR-375 in cancer. Int J Cancer 2014; 135: 1011-1018 [PMID: 24166096 DOI: 10.1002/ijc.28563]
44. Pearn L, Fisher J, Burnett AK, Darley RL. The role of PKC and PDK1 in monocyte lineage specification by Ras. Blood 2007; 109: 4461-4469 [PMID: 17255356 DOI: 10.1182/blood-2006-09-047217]
45. El Ouaamari A, Baroukh N, Martens GA, Lebrun P, Pipeleers D, van Obberghen E. miR-375 targets 3′-phosphoinositide-dependent protein kinase-1 and regulates glucose-induced biological responses in pancreatic beta-cells. Diabetes 2008; 57: 2708-2717 [PMID: 18591395 DOI: 10.2337/db07-1614]
46. Song SD, Zhou J, Zhou J, Zhao H, Cen JN, Li DC. MicroRNA-375 targets the 3-phosphoinositide-dependent protein kinase-1 gene in pancreatic carcinoma. Oncol Lett 2013; 6: 953-959 [PMID: 24137444 DOI: 10.3892/ol.2013.1510]
47. Meuillet EJ, Moses SA, Lucero-Acuna A, Guzman R, Jeffrey J, and Pagel M. Nanoparticles delivery of a novel AKT/PDK1 inhibitor inhibits pancreatic cancer tumor growth. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR. Cancer Res 2012; 72 (8 Suppl): Abstract nr 3752
48. Diep CH, Zucker KM, Hostetter G, Watanabe A, Hu C, Munoz RM, Von Hoff DD, Han H. Down-regulation of Yes Associated Protein 1 expression reduces cell proliferation and clonogenicity of pancreatic cancer cells. PLoS One 2012; 7: e32783 [PMID: 22396793 DOI: 10.1371/journal.pone.0032783]
49. Rieder S, Michalski CW, Friess H, Kleeff J. Insulin-like growth factor signaling as a therapeutic target in pancreatic cancer. Anticancer Agents Med Chem 2011; 11: 427-433 [PMID: 21492074]